A Phase 1 Trial of JMT108 in Adults with Advanced Solid Tumors
Phase 1
270
about 3.8 years
18+
3 sites in NC, TX, VA
What this study is about
Researchers are testing a new drug called JMT108, which is an antibody treatment, to see if it's safe and effective for adults who have advanced solid tumors. The trial will involve giving JMT108 through intravenous injection every two weeks until the doctor decides that stopping treatment is best. Participants will be followed up regularly to monitor their response to the drug.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take JMT108
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of participants with Dose Limiting Toxicities as assessed by NCI CTCAE v5.0 (excluding cytokine release syndrome, CRS).
Secondary: JMT 108 Pharmacokinetics: Clearance (CL), JMT108 Objective response rate (ORR), JMT108 Pharmacokinetics: Area under the concentration time curve over the dosing interval, JMT108 Pharmacokinetics: Elimination half-life (t1/2)
Oncology